Each capsule contains Mefenamic Acid 250mg
Medicap contains an analgesic with anti-inflammatory and antipyretic action.
Medicap is indicated for the relief of muscular aches and sprains,
toothache, headache, bursitis, dysmenorrhoea and mild to moderate pain in
Adults: Two capsules initially, followed by one capsule four times a day,
with or after food.
Do not use in patients with ulceration or inflammation of the
gastrointestinal tract, impaired renal or hepatic function, in
hypersensitive patients and in pregnancy.
Discontinue treatment if diarrhoea or rashes occur.
Use with caution in epilepsy and in asthmatic patients.
NSAID: Risk of GI ulceration, bleeding and perforation
Serious GI toxicity such as bleeding, ulceration and perforation can occur
at any time with or without warning symptoms, in patients treated with NSAID
therapy. Although minor upper GI problems (e.g. dyspepsia) are common,
usually developing early in therapy, prescribers should remain alert for
ulceration and bleeding in patients treated with NSAIDs even in the absence
of previous GI tract symptoms.
Studies to date have not identified any subset of patients not at risk of
developing peptic ulceration and bleeding. Patients with prior history of
serious adverse events and other risk factors associated with peptic ulcer
disease (e.g. alcoholism, smoking, corticosteroid therapy) are at increased
risk. Elderly or debilitated patients seems to tolerate ulceration or
bleeding less than other individuals and account for most spontaneous
reports for fatal GI events.
The effects of lithium therapy may be potentiated by mefenamic acid.
These may include gastrointestinal disturbances, bleeding, occasionally
peptic ulceration, hypersensitivity reactions; skin rashes, drowsiness,
dizziness, headaches and haematological effects such as haemolytic anaemia
In cases of overdosage and poisoning, hospital admission is strongly
advised. Symptoms include severe form of side-effects and convulsions.
Aspiration and gastric lavage may be necessary. Activated charcoal may be
useful in reducing absorption of mefenamic acid in acute cases. Symptomatic
and supportive treatment may be given.
5 years from the date of manufacture.
Blue / light blue hard gelatin capsules printed with "XSP" in dispensing
pack of 1000's.
Store below 30°C.